Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.

Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.

Abstract: The invention is directed to monocot plant seed products comprising human serum albumin, and to methods of making said monocot plant seed products comprising human serum albumin and to therapeutic compositions comprising them.

Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.

Abstract: The invention is directed to seed and seed extract compositions containing levels of a human milk protein between 3-40% or higher of the total protein weight of the soluble protein extractable from the seed. Also disclosed is a method of producing the seed with high levels of extractable human milk protein. The method includes transforming a monocotyledonous plant with a chimeric gene having a protein-coding sequence encoding a protein normally present in human milk under the control of a seed maturation-specific promoter. The method may further includes a leader DNA sequence encoding a monocot seed-specific transit sequence capable to target a linked milk protein to a storage body.

Abstract: The invention is directed to food and food additive compositions comprising one or more human milk proteins produced in the seeds of a transgenic plant and methods of making the same. The invention is further directed to improved infant formula comprising such food supplement composition.

Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.

Abstract: The present invention relates, generally, to oral formulations including one or more recombinantly-produced human milk proteins. The formulations of the present invention may be used to prevent the onset of diarrhea in patients who have been or will be exposed to one or more agents known to cause diarrhea, and to prevent the recurrence of diarrhea in a patient recovering therefrom. The formulations may also be used in the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The formulations may also be beneficially administered in accordance with methods for promoting the development of healthy intestinal flora in a human patient.

Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.

Abstract: The invention is directed to seed and seed extract compositions containing levels of a human milk protein between 3-40% or higher of the total protein weight of the soluble protein extractable from the seed. Also disclosed is a method of producing the seed with high levels of extractable human milk protein. The method includes transforming a monocotyledonous plant with a chimeric gene having a protein-coding sequence encoding a protein normally present in human milk under the control of a seed maturation-specific promoter. The method may further includes a leader DNA sequence encoding a monocot seed-specific transit sequence capable to target a linked milk protein to a storage body.

Abstract: The invention is directed to seed and seed extract compositions containing levels of a human milk protein between 3-40% or higher of the total protein weight of the soluble protein extractable from the seed. Also disclosed is a method of producing the seed with high levels of extractable human milk protein. The method includes transforming a monocotyledonous plant with a chimeric gene having a protein-coding sequence encoding a protein normally present in human milk under the control of a seed maturation-specific promoter. The method may further includes a leader DNA sequence encoding a monocot seed-specific transit sequence capable to target a linked milk protein to a storage body.

Abstract: The invention is directed to food and food additive compositions comprising one or more human milk proteins produced in the seeds of a transgenic plant and methods of making the same. The invention is further directed to improved infant formula comprising such food supplement composition.

Abstract: A method of producing human serum albumin (HSA) in monocot plant seeds, by transforming a monocot plant cell with a chimeric gene containing a promoter from the gene of a maturation-specific monocot plant storage protein, a first DNA sequence operably linked to the promoter and encoding a signal sequence, and a second DNA sequence linked in translation frame with the first DNA sequence and encoding HSA, where the first DNA sequence and the second DNA sequence together encode a fusion protein containing an N-terminal signal sequence and the HSA; growing a monocot plant from the transformed monocot plant cell for a time sufficient to produce seeds containing the HSA; and harvesting the seeds from the plant.

Abstract: The invention is directed to food and food additive compositions comprising one or more human milk proteins produced in the seeds of a transgenic plant and methods of making the same. The invention is further directed to improved infant formula comprising such food supplement composition.

Abstract: The invention is directed to seed and seed extract compositions containing levels of a human milk protein between 3-40% or higher of the total protein weight of the soluble protein extractable from the seed. Also disclosed is a method of producing the seed with high levels of extractable human milk protein. The method includes transforming a monocotyledonous plant with a chimeric gene having a protein-coding sequence encoding a protein normally present in human milk under the control of a seed maturation-specific promoter. The method may further includes a leader DNA sequence encoding a monocot seed-specific transit sequence capable to target a linked milk protein to a storage body.

Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.

Abstract: The invention is directed to food and food additive compositions comprising one or more human milk proteins produced in the seeds of a transgenic plant and methods of making the same. The invention is further directed to improved infant formula comprising such food supplement composition.

Abstract: The invention is directed to improved animal feed compositions comprising one or more milk proteins produced in the seeds of a transgenic plant and methods of making and using the same.